860 related articles for article (PubMed ID: 28209992)
1. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors.
Ashkenazi A; Fairbrother WJ; Leverson JD; Souers AJ
Nat Rev Drug Discov; 2017 Apr; 16(4):273-284. PubMed ID: 28209992
[TBL] [Abstract][Full Text] [Related]
2. Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy.
Suvarna V; Singh V; Murahari M
Eur J Pharmacol; 2019 Nov; 862():172655. PubMed ID: 31494078
[TBL] [Abstract][Full Text] [Related]
3. Targeting the B-cell lymphoma 2 anti-apoptotic proteins for cervical cancer treatment.
Abdul Rahman SF; Xiang Lian BS; Mohana-Kumaran N
Future Oncol; 2020 Oct; 16(28):2235-2249. PubMed ID: 32715755
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic inhibition of BCL-2 and related family members.
Levy MA; Claxton DF
Expert Opin Investig Drugs; 2017 Mar; 26(3):293-301. PubMed ID: 28161988
[TBL] [Abstract][Full Text] [Related]
5. Therapeutics targeting Bcl-2 in hematological malignancies.
Ruefli-Brasse A; Reed JC
Biochem J; 2017 Oct; 474(21):3643-3657. PubMed ID: 29061914
[TBL] [Abstract][Full Text] [Related]
6. The rise of apoptosis: targeting apoptosis in hematologic malignancies.
Valentin R; Grabow S; Davids MS
Blood; 2018 Sep; 132(12):1248-1264. PubMed ID: 30012635
[TBL] [Abstract][Full Text] [Related]
7. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
Leverson JD; Phillips DC; Mitten MJ; Boghaert ER; Diaz D; Tahir SK; Belmont LD; Nimmer P; Xiao Y; Ma XM; Lowes KN; Kovar P; Chen J; Jin S; Smith M; Xue J; Zhang H; Oleksijew A; Magoc TJ; Vaidya KS; Albert DH; Tarrant JM; La N; Wang L; Tao ZF; Wendt MD; Sampath D; Rosenberg SH; Tse C; Huang DC; Fairbrother WJ; Elmore SW; Souers AJ
Sci Transl Med; 2015 Mar; 7(279):279ra40. PubMed ID: 25787766
[TBL] [Abstract][Full Text] [Related]
8. Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics.
Yu L; Liu S
Semin Cancer Biol; 2013 Dec; 23(6 Pt B):553-60. PubMed ID: 24012660
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance.
Shahar N; Larisch S
Drug Resist Updat; 2020 Sep; 52():100712. PubMed ID: 32599435
[TBL] [Abstract][Full Text] [Related]
10. BCL-2 as therapeutic target for hematological malignancies.
Perini GF; Ribeiro GN; Pinto Neto JV; Campos LT; Hamerschlak N
J Hematol Oncol; 2018 May; 11(1):65. PubMed ID: 29747654
[TBL] [Abstract][Full Text] [Related]
11. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
Merino D; Lok SW; Visvader JE; Lindeman GJ
Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
[TBL] [Abstract][Full Text] [Related]
12. Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.
Vogler M; Walter HS; Dyer MJS
Br J Haematol; 2017 Aug; 178(3):364-379. PubMed ID: 28449207
[TBL] [Abstract][Full Text] [Related]
13. Targeting BCL-2-like Proteins to Kill Cancer Cells.
Cory S; Roberts AW; Colman PM; Adams JM
Trends Cancer; 2016 Aug; 2(8):443-460. PubMed ID: 28741496
[TBL] [Abstract][Full Text] [Related]
14. Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise.
Sarosiek KA; Letai A
FEBS J; 2016 Oct; 283(19):3523-3533. PubMed ID: 26996748
[TBL] [Abstract][Full Text] [Related]
15. Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules.
Yap JL; Chen L; Lanning ME; Fletcher S
J Med Chem; 2017 Feb; 60(3):821-838. PubMed ID: 27749061
[TBL] [Abstract][Full Text] [Related]
16. Peptide screening to knockdown Bcl-2's anti-apoptotic activity: implications in cancer treatment.
Raghav PK; Verma YK; Gangenahalli GU
Int J Biol Macromol; 2012 Apr; 50(3):796-814. PubMed ID: 22155216
[TBL] [Abstract][Full Text] [Related]
17. The Bcl-2 family: structures, interactions and targets for drug discovery.
Kvansakul M; Hinds MG
Apoptosis; 2015 Feb; 20(2):136-50. PubMed ID: 25398535
[TBL] [Abstract][Full Text] [Related]
18. Pro-apoptotic activity of BH3-only proteins and BH3 mimetics: from theory to potential cancer therapy.
Hartman ML; Czyz M
Anticancer Agents Med Chem; 2012 Oct; 12(8):966-81. PubMed ID: 22263800
[TBL] [Abstract][Full Text] [Related]
19. A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics.
Knight T; Luedtke D; Edwards H; Taub JW; Ge Y
Biochem Pharmacol; 2019 Apr; 162():250-261. PubMed ID: 30668936
[TBL] [Abstract][Full Text] [Related]
20. The BCL-2 arbiters of apoptosis and their growing role as cancer targets.
Adams JM; Cory S
Cell Death Differ; 2018 Jan; 25(1):27-36. PubMed ID: 29099483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
